Background: In clinical practice, treatment sequences of biologicals are applied for active fistulising Crohn's disease, however underlying health economic analyses are lacking. Objective: The purpose of this study was to analyse the cost-effectiveness of different biological sequences including infliximab, biosimilar-infliximab, adalimumab and vedolizumab in nine European countries. Methods: A Markov model was developed to compare treatment sequences of one, two and three biologicals from the payer's perspective on a five-year time horizon. Data on effectiveness and health state utilities were obtained from the literature. Country-specific costs were considered. Calculations were performed with both official list prices and estimated real prices of biologicals. Results: Biosimilar-infliximab is the most cost-effective treatment against standard care across the countries (with list prices: E34684-E72551/quality adjusted life year; with estimated real prices: E24364-E56086/quality adjusted life year). The most cost-effective two-agent sequence, except for Germany, is the biosimilar-infliximab-adalimumab therapy compared with single biosimilar-infliximab (with list prices: E58533-E133831/quality adjusted life year; with estimated prices: E45513-E105875/quality adjusted life year). The cost-effectiveness of the biosimilar-infliximab-adalimumab-vedolizumab three-agent sequence compared wit biosimilar-infliximab -adalimumab is E87214-E152901/quality adjusted life year. Conclusions: The suggested first-choice biological treatment is biosimilar-infliximab. In case of treatment failure, switching to adalimumab then to vedolizumab provides meaningful additional health gains but at increased costs. Inter-country differences in cost-effectiveness are remarkable due to significant differences in costs.
. The suggested first-choice biological treatment is bsIFX.
In case of treatment failure, switching to adalimumab then to vedolizumab provides meaningful additional health gains but at increased costs.
Introduction
Fistulising Crohn's disease (CD) can lead to significant impairment in health-related quality of life and imposes substantial burden both on patients and society. 1, 2 Fistulas are often difficult to treat and result in significant costs through the use of medication, surgical intervention and the need for hospitalisation. 3 Biological drugs has dramatically changed the treatment of CD. Randomised controlled trials (RCTs) established the clinical efficacy and safety of infliximab (IFX) for the treatment of fisultising CD, using fistula closure as primary endpoint. 4, 5 The scientific evidence for adalimumab (ADA) and vedolizumab (VEDO) is weaker as their effects were examined in subgroups of patients with fistulising CD in RCTs but only as secondary endpoints. [6] [7] [8] [9] [10] [11] IFX is the only biological drug that is specifically indicated for the treatment of adults with fistulising CD, but in clinical practice ADA and VEDO are also used to treat fistulising CD. [12] [13] [14] [15] Access to biologicals varies significantly between countries largely driven by budgetary constraints. 16, 17 Biological therapy and hospitalisation are the main cost drivers in CD, although studies focusing specifically on fistulising CD are scarce. 1, 2, 18, 19 Biosimilars, due to their lower price, have the potential to improve access to treatment and achieving substantial savings relative to the reference medical products. The first biosimilar monoclonal antibody, biosimilar-infliximab (bsIFX) was approved by the European Medicines Agency (EMA) in 2013 and U.S. Food and Drug Administration (FDA) in 2016 for the same indications as the originator molecule. 20 Although bsIFX is already used in many countries, few studies have dealt with its health economic aspects. Budget impact analyses suggest that significant savings can be achieved with bsIFX in CD. 21, 22 Three cost-utility studies of biological treatment in fistulising CD assessed the cost-effectiveness of IFX therapy in comparison with standard care from the third-party payers' perspective. [23] [24] [25] According to our knowledge, no health economic analyses with ADA, VEDO and bsIFX have been published yet. Intercountry comparisons are also lacking in the literature. More importantly, there is no cost-effectiveness evidence on the sequential use of biological treatment in fistulising CD. Health gains and costs of these treatment sequences have to be analysed and compared to identify the most cost-effective treatment strategy, particularly since the advent of including biosimilars.
The aim of our study was to analyse the cost-effectiveness of the different treatment sequences with available biologicals (IFX, bsIFX, ADA, VEDO), for the treatment of fistulising CD in nine European countries, namely in Belgium, France, Germany, Hungary, Italy, Spain, Sweden, the Netherlands and the UK.
Materials and methods

Model overview
A Markov model was developed to analyse the costeffectiveness of treatment sequences including bsIFX for the treatment of patients with active fistulising CD ( Figure 1 ). Model states are described by the health states and the therapies (Table 1) . Health states were defined by fistula healing related primary and secondary endpoints from RCTs.
The model focuses solely on fistulising CD and does not take account of treatment effects on luminal CD symptoms (e.g. improvement of Crohn's Disease Activity Index (CDAI) score).
At the end of each subsequent model cycle, patients either remained in the same model state or moved to a different one. The model runs in three-month cycles representing the course of the disease by time and the time horizon is five years. Patients could make transitions between model states at the end of a cycle. These movements are represented by the arrows on Figure 1 .
In the cost-effectiveness model, first we compared single biological drug treatment with standard (non-biological) care. Then different treatment sequences of multiple biologicals were compared with each other. If more than one biological was included in a treatment sequence, it was assumed that all patients who get to the model state 'D' would immediately start with the subsequent biological therapy and moved to model state 'A'. Once the patients went through all available biologicals, biological treatment could not be restarted again and they continued with non-biological standard care in the model state 'D' or moved to model state 'E'. Patients receiving non-biological standard care could move from model state 'D' to model states 'A' or 'C', but this was allowed only once during the time horizon of the model. From model state 'D' patients could move to model state 'E'. Patients with successful major fistula surgery moved to model state 'F'. Patients with unsuccessful first surgery went through a second procedure, however a maximum of two major fistula surgeries was allowed during the time horizon of the model. Combining fistula surgery with biological treatment can have beneficial effects however, not all patients have surgery alongside the initiation of biological drug treatment. [26] [27] [28] Hence, the model linked minor fistula surgery to the 'Initiation of biologic treatment' model state but assumed that this type of intervention applied to only 30% of the patient population.
Patients
The cost-effectiveness model was populated with patients with fistulising active CD who (a) had single or multiple draining abdominal and/or perianal fistulas at baseline; (b) who had not responded to conventional treatment (including antibiotics, drainage and immunosuppressive therapy); and (c) were eligible for biological treatment. These inclusion criteria correspond with the inclusion criteria of the only RCT designed specifically for fistulising CD, 4 with the fistulising subgroups of other RCTs in CD, as well as with the drug indications. 5, 8, 9 We assumed that the average age of the patients was 40 years and the average weight was 65 kg (standard deviation (SD) ¼ 16). 29 These figures are in line with the baseline characteristics of patients in the Present et al. study of 1999, 4 and other fistulising subgroups in RCTs. 5, 8, 9 Comparison of treatment sequences
In the cost-effectiveness model we compared different treatment sequences including the available biologicals as well as non-biological standard care. Each treatment sequence could include a maximum of three different biologicals: IFX, bsIFX, ADA and VEDO followed by standard care. Each biological could appear only once in the treatment sequence. First, we calculated the costeffectiveness of each biological drug (IFX, bsIFX, ADA and VEDO) followed by standard care compared with non-biological standard care. In the second step, we took the most cost-effective single biological and analysed the cost-effectiveness of adding a second biological to the sequence. In the third step, the most cost-effective two-item sequence was chosen and we explored the cost-effectiveness of adding a third biological.
Transition probabilities
Clinical efficacy data were derived from RCTs and were used to calculate transition probabilities. In the RCTs, fistulising CD-related inclusion criteria were typically the presence of single or multiple draining abdominal or perianal fistulas of at least three months' duration as a complication of CD, concurrent therapies for CD in stable doses were permitted and patients were excluded from the study if they had a stricture or abscess for which surgery might be indicated. In RCTs where fistulising patients were only a subgroup of the sample, moderate or severe active CD (as measured by the CDAI score) was a criterion of inclusion. Patients were biological naive in some RCTs 4,5 and have already had previous exposure to anti-tumour Necrosis Factor Alpha (anti-TNF-alpha) treatment in others. 8, 9, 30 Table 2 shows the transition probabilities of movements between model states. Transition probabilities were calculated based on efficacy data from RCTs and cohorts, 4, 5, 8, 9, 26, [31] [32] [33] and some estimations had to be applied due to lack of epidemiological data in fistulising CD. We used country-based mortality data of the general population and a higher mortality rate was considered for 'C', 'D' and 'E' model states (Table 2) . 34 
Costs and outcomes
The analyses were performed from the third-party payer perspective. IFX has patient weight-dependent dosing, the remaining portion of drug in the vial is either used (no wasting) or not (wasting) for the treatment of another patient. In the base case we considered no wasting for IFX and for bsIFX. Country-specific unit costs were considered based on official price lists and available sources to calculate health care utilisation costs.
At first we used the official list prices of biologicals (see Table 3 ). List prices represent the maximum prices, real prices are lower but not publicly available. Thus, we repeated the calculations using a 30% price decrease for bsIFX and IFX, and a 20% decrease for ADA (as biosimilar-ADA is not yet available, a lower real price reduction is assumed for ADA). VEDO was registered for CD in 2014, therefore we assumed no decrease in prices. Administration costs for biologicals were considered only for infusions (bsIFX, IFX, VEDO) as the administration cost of subcutaneous injections (ADA) is usually minor. For standard care we considered the cost of sulfasalazine, 2000 mg/day and 20 mg prednisolone/ day. In this patient population other per os drugs are also used such as azathioprine and/or antibiotics, which would result in similar costs. Both the items considered for the monitoring of patients and their frequency varied according to the treatments applied and also across countries. Monitoring included routine laboratory tests (blood cell count, liver and kidney function test, albumin, iron, ferritin, C-reactive protein, urine analysis, faecal calprotectin test, outpatient visit, chest x-ray, abdominal ultrasound, magnetic resonance and endoscopy (rectosigmoidoscopy and colonoscopy). Non-surgical hospitalisation and costs were considered only for 40% of patients in model state 'D'. Informal care and transportation costs were not included.
Utility values were attached to each model state to calculate quality adjusted life years (QALYs) in costeffectiveness analyses. Few data are available on the utility of health states of patients with fistulising CD. 25, 35 We applied utility weights presented by Lindsay at al. in 2008 25 ( Table 1) . Discounted costs and outcomes were calculated on a five-year time horizon.
Sensitivity analyses
The structural uncertainty of the model was evaluated using one-way sensitivity analysis varying parameters such as price, time horizon, patients' age and 34 The source of Life Tables: EUROSTAT. Due to the lack of data we assume that the probability of moving from 'Incomplete healing' to 'Complete healing' model state is 0. Due to the lack of data for fistulising patients, we assume that the efficacy of the 2nd and 3rd biological treatment will decrease by 10% (regardless of the agent). weight, health state utilities, cost of surgery and inpatient care, discounting rates and wasting of remaining drugs in the vial. Productivity loss was not included in the base case analysis but was considered in the sensitivity analysis providing an assessment from the societal perspective. A temporary productivity loss of 20-day sick leave per year (multiplied by average gross daily wages of the countries) was considered for 'A', 'D' and 'E' model states. Parameter uncertainty (transitional probabilities, costs, utility weights, patients' characteristics) was evaluated using probabilistic sensitivity analysis.
Results
Cost-effectiveness analyses (base case)
Incremental costs, QALY gains and the incremental cost-effectiveness ratios (ICERs) are presented in Table 4 by countries. 
Single biologicals compared with standard care -list price
Given the same clinical efficacy and safety for IFX and bsIFX, additional QALY gains compared with standard care were equal and varied between 0.244-0.252 QALY across countries due to differences in mortality and discount rates. Lower additional QALY gains were observed for ADA and VEDO in all the nine countries, 0.113-0.136 and 0.162-0.168 QALY, respectively. In six countries where the list prices of bsIFX were lower than of IFX (Germany, Hungary, Italy, Spain, Sweden and the UK), the additional costs compared with standard care were lower for bsIFX (varied between E8450-E17854) than for IFX (varied between E9697-E23512), and the highest were for VEDO (varied between E14117-E23295). Germany, Italy and the Netherlands are exceptions where the additional cost of the VEDO scenario was slightly lower than IFX (Table 4 ). The additional cost of ADA compared with standard care varied between E7941-E17480. The ICER (compared with standard care) was the lowest for bsIFX in all the nine countries and varied between E34684-E72551/QALY. Due to the same list prices of bsIFX and IFX, the ICERs of these two drugs were identical in Belgium, France and the Netherlands. The ICERs were between E38420-E95540/QALY for IFX, E60646-E132071/ QALY for ADA, and E83806-E142118/QALY for VEDO (Table 4) .
Treatment sequences with two or three biologicals -list prices
Since bsIFX was the most cost-effective treatment as a one-agent treatment sequence, this was chosen as a comparator for treatment sequences with two and three biologicals. Adding a second biological to the treatment sequence after bsIFX provided additional QALY gains (0.103-0.133) compared with bsIFX alone but at larger additional costs (E6129-E18700). The bsIFXÀADA was the most cost-effective twoagent treatment sequence in all countries with ICERs (compared with bsIFX) between E58533-E133831/ QALY. Germany was an exception where the bsIFX-VEDO sequence resulted in a lower ICER than the bsIFX-ADA sequence. The ICERs of the bsIFX-VEDO treatment sequence were between E83808-E145582/QALY (Table 4) . Adding a third biological (VEDO) to the two-agent treatment sequence provided additional QALY gains (compared with bsIFX-ADA sequence: 0.113-0.120) but at larger additional costs (E10444-E17587). The ICERs varied between E87214-E152901/QALY. In Germany, adding ADA after bsIFX-VEDO sequence resulted in an ICER of 140666/QALY compared with bsIFX-VEDO.
Cost-effectiveness with estimated real prices
We repeated the calculations applying 30% decrease in the list price of IFX and bsIFX, and 20% for ADA in Table 4 as only drug costs were modified. Vedolizumab price was not discounted hence no change in the vedolizumab versus standard care and the bsIFX-VEDO vs bsIFX scenario.
each country. This resulted in a 19-30% decrease of the ICERs for bsIFX compared with standard care (E24364-E56086/QALY), a 21-30% decrease for IFX (E27141-E67762), and a 14-20% decrease for ADA (E48713-E107255). The ICER of the bsIFX-ADA treatment sequence (compared with bsIFX) decreased by 20-22% (E45513-E105875/QALY). Applying these estimated real prices resulted in the bsIFXÀADA sequence becoming the most beneficial among the two-agent sequences, also in Germany (results are presented in Table 5 ).
One-way sensitivity analysis
One-way sensitivity analyses results for bsIFX compared with standard care are presented in Table 6 . The effects were comparable for other treatment sequences as well. Taking into account productivity loss, ICERs decreased by 6-27%. Also, a 10% increase in utility weights decreased the ICERs by 9%, and a 10% decrease increased the ICERs by 11%. On a 10-year time horizon ICERs decreased by 5-6%. The results were the least sensitive to discounting (À5 to À1%), to the 10% change in the hospitalisation (surgery, inpatient stay) costs (À0.3% to þ0.3%) and to the AE5 year change in the age of patients (-0.5% to þ0.3%).
Regarding parameters relating to the weight dependent dosing of bsIFX and IFX, the AE5 kg change in patients' weight resulted in a change of AE8% in ICERs. Inclusion of wasting of infliximab vials increased the ICERs by 10-15%.
Probabilistic sensitivity analysis (PSA)
Results were robust for the changed in input data and assumptions. For example in the UK, The 95% confidence intervals of the ICERs calculated by the simulations were E45788-E97677/QALY for bsIFX and E51081-E94182/QALY for IFX, both compared with standard care.
In 69% of the simulations, the ICER of bsIFX remained under a 2 Â GDP per capita financial threshold in the UK. This was the case in 56% of the cases for IFX.
Discussion
In this study we assessed the cost-effectiveness of single biologicals and treatment sequences in comparison with non-biological standard care and with each other for adult patients with fistulising active CD in nine European countries. This is the first cost-effectiveness analysis with bsIFX, ADA and VEDO in fistulising CD, and also the first which assessed the costeffectiveness of biological treatment sequences including two and three biological substances. Nine European countries were involved in the analyses which enables us to make cross-country comparisons. Also, this is the first study to analyse the cost-effectiveness of biologicals in fistulising CD not only from third-party payers but also from the societal perspective.
In scenarios including a single biological drug, bsIFX was the most cost-effective and VEDO was the least cost-effective treatment compared with non- biological standard care. In France, the Netherlands and in Belgium the cost-effectiveness of IFX and bsIFX were identical as the list prices of these two drugs were equal (Table 4) . Starting treatment with bsIFX was not only the most cost-effective scenario but also IFX had the highest level of clinical evidence that supports this strategy. As a second biological treatment following bsIFX, ADA provided better cost-effectiveness results compared with VEDO, except in Germany. Including VEDO as a third agent in the treatment sequence (after bsIFX and ADA) provides high cost-effectiveness ratios.
The use of bsIFX in the treatment sequences instead of IFX, reduces the ICERs to below a threshold of 2 Â GDP per capita across all the nine countries. The introduction of bsIFX has made biological treatment more affordable, providing cost-savings, thus it improves access to biological therapy.
The cross-country differences in ICERs can be largely explained by the differences of the list prices of biologicals (i.e. higher biological prices resulting higher ICERs). The highest ICERs were observed in Germany (Table 4) due to the highest list prices (Table 3) .
It is important to point out that real purchasing prices are substantially lower than list prices, but are not publicly available, and can vary even within a country due to local tenders. Based on personal communication, the price of bsIFX is about 50% lower than the list price of the originator product. Thus, we performed repeat calculations applying a 30% price decrease for bsIFX and IFX, and a 20% decrease for ADA list prices to get cost-effectiveness ratios which we assume to better reflect real world practice ( Table 5) . As a result, ICERs decreased by 19-30%, although the optimal treatment strategies remained the same. Using this approach in Germany, ADA became the most cost-effective treatment as a second treatment option after bsIFX.
Comparison with the available three cost-effectiveness studies in fistulising CD is hampered by methodological differences. Arseanau and colleagues (2001) evaluated IFX therapy in comparison with standard care on a one-year time horizon in the USA, and the ICER varied from $355,450 to $377,000/QALY. 23 Clarke and colleagues (2003) analysed IFX against standard care in the UK and the ICERs were between £82,000-£123,000/QALY. 24 Lindsay et al. (2008) found a somewhat lower ICER (£29,752 per QALY) with IFX compared with standard care in the UK on a five-year horizon. 25 This cost-effectiveness model has several limitations. The model movements represent clinical practice, however we applied some simplifications. We did not calculate with the effects of discontinuation of biological therapy, and assumed that spontaneous healing from the refractory state is only allowed once in the model. In addition, patients could go through surgery a maximum of two times during the full time horizon of the model. Nevertheless, the model results are robust despite these assumptions as they are identical in the active and comparator scenarios. The model focuses on fistulising CD and treatment effects on luminal CD symptoms were not captured. Specifically, we focused on endpoints related to fistula healing in the model and did not take into account the potential improvements in the underlying CD (e.g. improvements in the CDAI score)). Thus, giving conservative estimations, we probably underestimated the efficacy of therapy in case of patients where fistula closure was not achieved but underlying CD activity improved. In these cases larger health gains are achieved on the same costs, resulting better cost-effectiveness ratios.
Due to the lack of data in fistulising CD, we did not calculate with the effects of dose-increases. However, dose increase occurs in everyday clinical practice in fistulising CD.
Transition probabilities between model states are key points in cost-effectiveness modelling. Due to the scarcity of evidence from RCTs we had to apply some estimations. For fistula healing as a primary outcome in RCTs, there is only evidence for IFX. Evidence for ADA and VEDO comes from subgroup analysis of RCTs.
We used country-specific costs in the model. However we could not consider all intercountry variations due to shortage of local data (such as patients' age, weight and efficacy), thus for some parameters we assumed no significant differences across the countries. Nevertheless, results of our sensitivity analysis suggest that in a country where the average weight of patients is þ5 kg, the ICERs increase by about 8%. Results were much less sensitive to changes in the age of patients, AE5 years change results in À0.5% to þ0.3% change in the ICERs. Moreover, health status and disease progression of patients initiating biological treatment in the real world might differ between jurisdictions due to variations in health care delivery structures, guidelines, clinical practice (e.g. surgical strategies, the level of multidisciplinary teamwork) and access (availability, affordability and acceptability) to biological treatment. 16, 36 These might result in some differences of effectiveness as well, however at a minor level compared with the overall treatment effects. Nevertheless, refinement of our results based on more precise, local evidence is to be encouraged. Our study revealed a remarkable deficiency of data in the literature on fistulising CD patients, a point we suggest should be considered in the development of CD registries and in publication strategies in the future.
In conclusion, as the number of biologicals is growing for fistulising CD the focus of cost-effectiveness analysis is moving to the comparison of treatment sequences. This is the first study which assessed the cost-effectiveness of biological treatment sequences in fistulising CD. We found that bsIFX was the most beneficial first treatment choice in all of the nine countries. Appling a second and third biological provides some additional health gain at a high cost. Significant differences were found in costs but only minor variations in health gains across countries.
Conclusion
In clinical practice, treatment sequences of biologicals are applied for active fistulising CD, however underlying health economic analyses are lacking. The suggested first-choice biological treatment is bsIFX. In case of treatment failure, switching to ADA then to VEDO provides meaningful additional health gains but at increased costs.
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